Sector News

FDA should be split up—and stop covering food, says White House

June 25, 2018
Life sciences

The FDA could become much smaller if a proposal by President Trump to separate the regulation of food and medicines comes into effect.

The current dual role makes no sense, according to a White House document that wants around 5,000 FDA staffers transferred to the U.S. Department of Agriculture so that all food regulation occurs under one roof. The current structure at the FDA is a relic of the early 1900s that “introduces greater risk, inefficiency, and inconsistency into the important work of ensuring food safety, which affects everyone in America.”

The plans would also see around $1.3 billion in budget transferred from the FDA—which would be rebadged as the “Federal Drug Agency”—to a new “Federal Food Safety Agency,” which would also be funded with around $1 billion in USDA money. The new FDA would then be able to “focus on its core responsibilities of drugs, devices, biologics, and tobacco,” the White House said.

The document gives one example of how the current system is flawed: the regulation of pizza. If it’s a cheese pizza, the FDA has the authority, but pepperoni falls under the USDA’s Food Safety and Inspection Services (FSIS). Have chicken as a topping? The FDA regulates their feed, but the FSIS inspects them at slaughter.

“In the long term, the Administration expects this proposal would result in improvements in food safety outcomes, policy and program consistency, and more efficient use of taxpayer resources,” it said.

The proposals are part of a sweeping reorganization plan that Trump wants to put in place to tackle “fragmented” decision-making at federal agencies, and the FDA changes come alongside plans to merge the Departments of Education and Labor into a single agency, as well as dozens of other initiatives covering housing, fisheries, environmental programs, humanitarian assistance and international development.

There’s still a long way to go before the plans could be enacted, as Congress would have to agree to the changes, but there does seem to be support for some degree of government reform. For instance, the General Accountability Office (GAO) has been highlighting the problems of food safety regulation for a long time, and earlier this year it published a report saying that—as of January—the FDA had still not set out a clear path for the implementation of food safety strategies in the 2016-2025 program.

It’s worth noting that the White House announcement came just ahead of an FDA “tweetorial” on the subject of food safety, with Commissioner Scott Gottlieb saying: “FDA takes our responsibility for assuring safety of the food supply seriously, and food safety is one of my highest priorities.”

FierceBiotech reached out to the FDA for comment on the proposals but hadn’t heard back by the time this article was published.

By Phil Taylor

Source: Fierce Biotech

comments closed

Related News

April 20, 2024

CureVac and MD Anderson Cancer Center partner to develop new cancer vaccines

Life sciences

CureVac and the University of Texas’s MD Anderson Cancer Center have announced a co-development and licensing agreement to develop novel messenger ribonucleic acid (mRNA)-based cancer vaccines. The strategic collaboration will focus on the development of differentiated cancer vaccine candidates in selected haematological and solid tumour indications with high unmet medical needs.

April 20, 2024

FUJIFILM plans $1.2 billion investment in major US manufacturing facility

Life sciences

FUJIFILM Corporation is planning to invest $1.2 billion to expand the planned FUJIFILM Diosynth Biotechnologies manufacturing facility in Holly Springs, North Carolina, US. This news follows the organisation’s announcement of a $2 billion investment in the facility in March 2021. This additional financial boost totals the investment to over $3.2 billion, FUJIFILM confirmed.

April 20, 2024

Sanofi cuts staff in Belgium as early-stage research dwindles

Life sciences

Sanofi’s global restructuring and downsizing is now fully underway, with layoffs stretching to the company’s Belgian offices. Belgian newspaper De Tijd reports that 67 employees have been laid off at a site in Ghent and 32 jobs are on the chopping block at Sanofi’s Belgium HQ in Diegem.

How can we help you?

We're easy to reach